5 Key Takeaways

• 1

  The UK aims to be a leading life science nation by 2030, but faces significant skills gaps and declining clinical trial numbers.

• 2

  Virtual reality (VR) is enhancing training for medicine makers by providing a cost-effective, scalable, and safe learning environment.

• 3

  The UK has seen a 41% decline in industry clinical trials from 2017 to 2021, impacting its global pharmaceutical standing.

• 4

  The RESILIENCE program has trained over 13,500 students through outreach and industry-relevant events since its inception.

• 5

  VR training allows for repetitive practice without material waste, addressing the high costs and complexities of traditional lab training.